3380353
doi
10.5281/zenodo.3380353
oai:zenodo.org:3380353
user-jacobmcauley_summer2019
Harding, Rachel
University of Toronto, Structural Genomics Consortium
Arrowsmith, Cheryl
University of Toronto, Structural Genomics Consortium
Edwards, Aled
University of Toronto, Structural Genomics Consortium
GAPDH Purification
McAuley, Jacob
University of Toronto, Structural Genomics Consortium
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
GAPDH
Huntingtin Interactome
Huntington's Disease
SGC
Structural Genomics Consortium
<p>Huntington’s Disease (HD) is a hereditary neurodegenerative disease; the cause of which is due to a CAG repeat extension in the HTT Gene. This extension is then translated into an elongation of exon 1 which is primarily composed of a disordered PolyQ repeat. Although the cause is known, the mechanism by which this extension affects the function of Huntingtin (HTT), the protein produced by the HTT Gene, has yet to be fully understood. A part of this difficulty is our lack of understanding of the role of normal HTT in our cells. To further our understanding of the role of HTT, we at the SGC have set out to explore the HTT interactome, which will give us a better idea of what specific interactions are modulated in HD. Our first step on this journey was to conduct a literature review alongside a BioID experiment to come up with a list of putative huntingtin interaction partners. One of the hits on the list was GAPDH. This means that we must obtain a pure sample of GAPDH for use in future experiments to further validate the claim that these proteins interact.</p>
Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG,Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
Zenodo
2019-08-13
info:eu-repo/semantics/other
3367321
user-jacobmcauley_summer2019
2
1579893938.283554
146240
md5:8061532a6a624791d9f69d10eba678c0
https://zenodo.org/records/3380353/files/Zp- 20190731 GAPDH.pdf
139585
md5:d2ed599e6fb8eaa24e74765c3b790723
https://zenodo.org/records/3380353/files/Zp- Production and Purification of GAPDH.pdf
public
10.5281/zenodo.3367321
isVersionOf
doi